Insulin Glargine + Lixisenatide (Suliqua)

Status:

Grey - after consultant/specialist initiation

Decision Date:

October 2020

Comments

GREY specialist initiation and stabilisation of dosage: restricted for those patients struggling to manage multiple injections. Ongoing specialist support should be maintained for patients on this treatment.

 Suliqua is available in two strengths:

• insulin glargine 100units/ml + Lixisenatide 50mcg/ml (Suliqua 10 - 40 pen)
•  insulin glargine 100units/ml + Lixisenatide 33mcg/ml (Suliqua 30 - 60 pen)
  

Prescriber must ensure the correct strength and number of dose steps are stated on the prescription.

Brown Drug Classifications

• 8. Exceptionality where a small cohort of patients may benefit from prescribing can be identified

search again